Sponsored content from Huge Alerts 
SRCRF Emerges as a Standout Junior Gold Explorer as Gold Breaks Above $5,000 an Ounce and Analysts See More Upside Ahead! Gold has surged to historic record highs above $5,000 per ounce, creating a powerful tailwind for high-quality gold exploration companies. With major banks and analysts continuing to project elevated gold prices into 2026, investors are increasingly looking for junior explorers with scale, grade, and jurisdictional strength. Scorpio Gold (OTCQB: SRCRF) is gaining attention as one of the most compelling opportunities in this environment, offering leveraged exposure to gold through its 100%-owned Manhattan District in Nevada’s prolific Walker Lane Trend. Scorpio Gold has already defined a 740,000-ounce inferred resource, delivered strong high-grade drill results, and identified 19 high-priority exploration targets across a large, consolidated land package with existing infrastructure, including a permitted mill. Backed by prominent investors Ross Beaty and Eric Sprott and fully funded for aggressive drilling, SRCRF is advancing a district-scale gold story with the potential for meaningful resource expansion as gold prices remain near record levels. Discover why SRCRF is emerging as one of the most closely watched junior gold explorers in Nevada as gold enters a new bull market
Wednesday's Bonus Article Johnson & Johnson Quietly Triggers a Trend Following Buy SignalWritten by Thomas Hughes. Date Posted: 1/23/2026. 
Article Highlights - Johnson & Johnson pulled back into a trend-following entry after its Q4 2025 release and guidance update.
- Analysts and institutional trends support the stock's price action and point to new highs in 2026.
- Capital return and capital return growth are factors, with both reliable for the foreseeable future.
Johnson & Johnson (NYSE: JNJ), amid the noise of Trump's Greenland agenda and renewed trade-war fears, is quietly executing its healthcare strategy: growing revenue and widening margins. A recent earnings release and 2026 guidance update, though strong, produced a short price pullback and a classic trend-following opportunity. 
A little-known government task force just wrapped up a 20-year project, and its findings could unlock access to a massive U.S. national asset. Under existing law, everyday Americans may now have a legal path to participate in what some are calling a once-in-a-generation opportunity.
Details are still flying under the radar, but that may not last. See the full briefing and how it works What is a trend-following signal? Assuming the trend is up, as it is with JNJ stock, a trend-following signal occurs when the price action retreats to a commonly used trend indicator—such as a moving average or trend line—and then confirms support at that level. This pattern affirms the presence of buyers and presents high potential for a rebound while derisking the entry point. The likely outcome is that the stock will resume its steady advance and set fresh highs in the near term. Johnson & Johnson's Healthy Business and Pipeline Underpin Stock Price Action Johnson & Johnson's Q4 results highlight the strength of its portfolio and pipeline. Revenue rose 9.1% year-over-year—nearly 200 basis points above expectations—driven by core strength in Innovative Medicine and MedTech, supplemented by acquisitions. Organic revenue grew 7.1% and adjusted revenue grew 6.1%; management expects to sustain a mid-single-digit pace in 2026. Margins were an area of strength in the report and were broadly in line with consensus expectations. Adjusted earnings improved significantly versus the prior year and rose more than 20%, bolstering an already-healthy balance sheet and supporting the capital-return outlook. Management's guidance was solid—and likely conservative. The company is targeting 6.7% revenue growth and margin improvements, both above consensus figures. Momentum in core segments—especially with blockbusters like Darzalex—and continued pipeline advancement could allow J&J to exceed its guidance next quarter. The company also reported positive results from several trials and has submitted its OTTAVA robotic surgical system for De Novo classification. If approved, OTTAVA would open a new revenue stream with potential for high-double-digit growth for several years. Johnson & Johnson Results Align With Bullish Analyst Trends Johnson & Johnson's bullish analyst trends are unlikely to abate given the Q4 strength and outlook. The 29 analysts tracked by MarketBeat rate the stock a Moderate Buy, and price targets have been rising. The consensus price target implies the stock is fairly valued and trading near the pre-release close. Still, the trend points toward the high end of the range—sufficient for roughly a 10% upside and a fresh all-time high. Institutions accumulated shares in 2025 and early 2026, which should help limit downside risk on any pullbacks. Johnson & Johnson's dividend is another reason analysts and institutions favor this stock. The payout yields nearly 2.5% even with shares near record highs, and it is expected to grow over time. J&J is a Dividend King with more than 60 consecutive years of annual increases. A relatively low payout ratio (around 50%) suggests modest, single-digit dividend increases are sustainable for the foreseeable future. Risks for JNJ shareholders in 2026 include ongoing talc litigation, competition from Stelara biosimilars, and execution risk tied to the expected OTTAVA launch. Talc litigation is being allowed to advance, with the plaintiff's expert testimony permitted—an evidentiary hurdle the company will have an opportunity to refute. Meanwhile, Stelara lost patent protection in 2025 and will face increasing biosimilar competition as the year progresses; Stelara sales (about 11.5% of 2024 revenue) fell more than 40% in 2025.
| 
Post a Comment
Post a Comment